Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Solid Biosciences develops gene therapies for Duchenne muscular dystrophy and rare heart conditions.
Solid Biosciences is a gene therapy company working on treatments for a rare muscle-wasting disease called Duchenne muscular dystrophy, plus a handful of uncommon heart conditions. Gene therapy is a way of fixing a disease at its root: instead of managing symptoms with drugs, you deliver a working copy of a broken gene into a patient's cells so the body can make the protein it was missing. For Duchenne, that missing protein is dystrophin, which muscles need to stay intact. Without it, boys born with the disease lose muscle strength early and often don't live past their twenties.
The company's lead program is called SGT-003, an experimental one-time infusion aimed at delivering a shortened but functional version of the dystrophin gene. Solid believes its delivery method, built on a harmless virus that carries the gene into muscle cells, may reach more muscle tissue and trigger a stronger response than earlier attempts by rivals. In early testing in a small number of boys, the company has reported encouraging signs, and it has said it plans to move toward a pivotal trial. The path is not guaranteed: the gene therapy field for Duchenne has suffered setbacks, including a patient death in a competitor's trial, and regulators have grown more cautious about how these treatments are tested. Solid doesn't sell anything yet. It earns no revenue from products, and like most clinical-stage biotech firms it burns cash to fund years of lab work, manufacturing, and trials. Its money comes largely from investors and from a partnership and licensing deal with Tenaya Therapeutics — actually a separate arrangement: Solid brought in capital and support through collaborations and public stock offerings. The real bet is that one of its programs wins regulatory approval and becomes a one-time treatment that payers will reimburse at a high price, which is how gene therapy companies eventually make money. Until then, it is a story about science and survival, not sales.
Solid was founded in 2013 by a father and son, Ilan and Carl Morris, after Carl was diagnosed with Duchenne. That personal origin shapes the company's urgency but also makes it one of several players chasing the same disease, alongside Sarepta Therapeutics and others. Its main risks are the usual biotech ones: trials can fail, manufacturing can go wrong, cash can run low, and a single safety scare in the field can hurt everyone. The upside is a disease with no cure, where a genuinely better treatment could matter enormously to patients and be worth a great deal to whoever gets there first.
Saved answer · last researched 16 Nov 2026